Loading
Life sciences · Journal article
Acs Nano · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract The lack of clear identification or understanding of the key perpetrators activating the tumor microenvironment (TME) impedes development of TME-modulating therapeutic strategies that could overcome the challenges associated with tumor growth, metastasis, and therapy resistance. Here, we report the development of a hybrid nanomaterial designed to genetically silence one key regulator, IGFBP2 (insulin-like growth factor binding protein 2), responsible for multicellular crosstalk within the TME. We demonstrated that silencing of IGFBP2 by this hybrid nanomaterial suppressed angiogenesis, stromal activation, and tumor cell phenotypes both in vitro and in vivo in preclinical models of ovarian cancer. Mechanistically, the hybrid nanomaterial utilizes the caveolae-mediated intracellular uptake pathway rather than a mixture of clathrin and caveolin as seen with a nonhybrid counterpart. Given the role of IGFBP2 as a prognostic factor for several cancers, and the absence of any small molecule inhibitor of IGFBP2, the current strategy may be exploited as a promising and generalized approach to target the TME and improve therapeutic outcomes in numerous cancers, including ovarian cancer